Get the Stockscreener App
0.5549
3.49%
0.0187
Pre-market:
.55
-0.0049
-0.88%
BiomX Inc stock is traded at $0.5549, with a volume of 978.85K.
It is up +3.49% in the last 24 hours and up +4.40% over the past month.
BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
See More
Previous Close:
$0.5362
Open:
$0.5701
24h Volume:
978.85K
Relative Volume:
0.18
Market Cap:
$6.19M
Revenue:
-
Net Income/Loss:
$-47.68M
P/E Ratio:
-0.0222
EPS:
-24.9619
Net Cash Flow:
$-23.09M
1W Performance:
-26.73%
1M Performance:
+4.40%
6M Performance:
-67.92%
1Y Performance:
-92.86%
1-Day Range:
$0.5308
$0.5907
1-Week Range:
$0.5165
$0.75
52-Week Range:
$0.3608
$14.71
BiomX Inc Stock (PHGE) Company Profile
Name
BiomX Inc
Sector
Industry
Phone
972 7 23942377
Address
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
Compare PHGE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
0.5549 | 6.19M | 0 | -47.68M | -23.09M | -24.96 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-21 | Initiated | Ladenburg Thalmann | Buy |
BiomX Inc Stock (PHGE) Latest News
Number of shareholders of BiomX Inc. – AMEX:PHGE - TradingView
PHGE Q4 2025 Earnings: Significant EPS Miss Amid Clinical-Stage LossesOne-Time Gain Impact - newsline.com
PHGE - Finviz
BiomX Wins NYSE Compliance Plan Extension to 2027 - TipRanks
BiomX Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
BiomX (PHGE) wins NYSE American plan period after equity deficit warning - Stock Titan
BiomX gets more time to fix NYSE listing compliance issues - Stock Titan
BiomX (PHGE) details Zorronet and Dr. Frucht Systems acquisition financials - Stock Titan
PHGE Should I Buy - Intellectia AI
BiomX Inc. Publishes Review on the Future of AI in Security Industry by Zorronet CEO Idan Wasserman - Quiver Quantitative
Why stadium security AI must learn crowd behavior, not just spot threats - Stock Titan
BiomX Company Profile & Introduction - Moomoo
Large new equity pool and board election at BiomX (PHGE) 2026 meeting - Stock Titan
· Analyst Forecast - MLQ.ai
PHGE Q4 2025 Earnings: Wider-than-Expected Loss Sends Shares LowerEarnings Weakness Phase - newsline.com
BiomX Inc. Enters Line of Credit Agreement and Issues 12% Convertible Promissory Note – SEC 8-K Filing June 2026 - Minichart
BiomX subsidiary launches mobile command app for operators - Investing.com
BiomX Issues Restricted Shares Under Mandragola Credit Facility - TipRanks
BiomX (NYSE: PHGE) converts debt to shares and grants 2M-share warrant - Stock Titan
BiomX Inc. Appoints Former Elbit Systems Chief Scientist Gabby Sarusi to Board of Directors - geneonline.com
BiomX announces CEO and board changes, appoints Michael Oster as chief executive - Investing.com
Another Prominent Defense Technology Leader Joins BiomX: Prof. Gabby Sarusi, Former VP and Chief Scientist at Elbit - The Manila Times
BiomX Inc. Appoints Prof. Gabby Sarusi as Strategic Advisor to Enhance Defense and Security Capabilities - Moomoo
Ex-Elbit defense scientist joins BiomX push into threat-detection tech - Stock Titan
BiomX expands Zorronet's AI C5ISR suite for secure on-premise defense and critical infrastructure use. - Pluang
Zorronet Brings Autonomous C5ISR to Hardened Sites Without Public Cloud Dependence - The Manila Times
AI security system moves on-site: no public cloud for hardened facilities - Stock Titan
PHGE Q4 2025 Earnings: EPS Miss of -$8.17 Amid Continued Clinical DevelopmentMid-Term Outlook - newsline.com
BiomX Appoints Roy Rousso as Chief Business Officer - The Globe and Mail
Deerfield funds report 8.09% BiomX (PHGE) ownership after warrant and preferred conversions - Stock Titan
BiomX Inc. Appoints Roy Rousso as Chief Business Officer Effective July 1, 2026 – Details of Consulting Agreement - Minichart
BiomX appoints Roy Rousso as Chief Business Officer - TradingView
BiomX (NYSE: PHGE) hires Roy Rousso as new Chief Business Officer - Stock Titan
BiomX Inc. (PHGE) Q4 2025 Earnings: EPS Misses by Wide Margin, No Revenue, Stock DeclinesEarnings Quality Analysis - The Legal Advocate
BiomX (PHGE) Appoints New Chief Business Officer to Strengthen L - GuruFocus
BiomX appoints Roy Timor-Rousso as chief business officer By Investing.com - Investing.com India
BiomX Inc. (PHGE) Slides 7%: Crucial Support Test Nears as Selling Pressure IntensifiesGrowth Factor - The Legal Advocate
BiomX (PHGE) Appoints New Chief Business Officer to Strengthen Leadership - GuruFocus
BiomX appoints Roy Timor-Rousso as chief business officer - Investing.com
BiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security Operations - The Manila Times
BiomX Inc. Announces the Appointment of Roy Timor-Rousso as Chief Business Officer - marketscreener.com
BiomX Inc. (PHGE) Q4 2025 Earnings: Deep EPS Miss Overshadowed by 98% Stock SurgeEBITDA Estimate Trend - newsline.com
PHGE Stock Jumps As BiomX Launches AI Command App - StocksToTrade
PHGE Stock Pops As BiomX Unveils AI Command App - timothysykes.com
BiomX Inc. (PHGE) Surges 10.5%: Can the Rally Hold Above $0.78 Support?Point of Control - Newser
PHGE Q4 2025 Earnings: EPS Misses Estimates Significantly, Stock Rises 10.5%Profit Margin Analysis - newsline.com
PHGE Q4 2025 Earnings: Severe EPS Miss as BiomX Continues Clinical DevelopmentSmart Trader Community - Newser
BiomX Inc Stock (PHGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):